Qritive.

A pathologist's diagnosis still begins the way it did a century ago: a thin slice of tissue on a glass slide, stained and studied under a microscope. Qritive, a Singapore healthtech company founded in 2017, is trying to make that slide smarter without asking the lab to throw out its microscope. Its software digitizes the whole-slide image, then runs artificial-intelligence modules that flag, grade and classify cancer for the pathologist to confirm.

The company was spun out of research at the National University of Singapore. Co-founder Aneesh Sathe earned a PhD in mechanobiology and built computer-vision systems to identify cancer cells; co-founder Kaveh Taghipour completed a PhD in natural-language processing. Together they framed cancer diagnosis as, in part, a machine-vision problem - and built a platform around it.

That platform is called Pantheon. It handles case management, slide viewing, synoptic reporting, telepathology and integration with lab information systems in a single window. On top of it sit the AI modules - prostate, colon, breast, gastric, lymph node metastasis and immunohistochemistry - that do the pattern recognition. The design choice that matters most is that all of it is vendor-agnostic: a lab can adopt the AI without replacing its existing scanners.

The payoff Qritive points to is consistency. In a collaborative study with Singapore General Hospital, the company's immunohistochemistry module was shown to reduce diagnostic subjectivity and discordance by 9.4 percent. In a field where two experts can grade the same slide differently, that number is the pitch.

Qritive sits in the computational-pathology segment of health AI, alongside firms such as Paige, PathAI, Ibex Medical Analytics, Owkin, Aiforia and Proscia, and competing with AI features baked into scanner and platform vendors like Philips and Sectra. Its differentiation is less about a single flagship algorithm and more about being the software layer that ties a lab's existing hardware together.

The business model is B2B software: Pantheon and the AI modules are licensed to hospitals, labs and pharmaceutical partners, typically on a subscription or per-use basis, with additional revenue from embedding Qritive AI inside larger diagnostics platforms. Third-party estimates put annual revenue near $3.1M and headcount around 12 - a small team leaning on partnerships and regulatory milestones to scale.

The tailwind is structural. Pathologist shortages, rising case volumes and the slow but real shift to digital slides have made AI-assisted reading more plausible than it was a decade ago, when digital pathology was perpetually "five years away." Qritive's wager is that the winners will be the companies willing to do the unglamorous integration and clearance work - not just the ones with the flashiest models.